Topic: Staphylococcus aureus
Pfizer's Staphylococcus aureus vaccine candidate was among a group of pipeline shots the company hoped could propel growth beyond Prevnar 13.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.
Pfizer's Prevnar turned in consensus-beating sales of $1.53 billion in Q4, thanks to government purchases internationally and in the U.S.